Novartis Pharms Corp Drug Patent Portfolio
Novartis Pharms Corp owns 2 orange book drugs protected by 19 US patents Given below is the complete list of Novartis Pharms Corp's drugs and the patents protecting them.
1. Entresto
Entresto is protected by 16 patents, out of which 6 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11058667 | Sacubitril-valsartan dosage regimen for treating heart failure |
09 May, 2036
(11 years from now)
| Active |
| US11135192 | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
22 Aug, 2033
(8 years from now)
| Active |
| US9517226 | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
22 Aug, 2033
(8 years from now)
| Active |
| US9937143 | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
22 Aug, 2033
(8 years from now)
| Active |
| US8877938
(Pediatric)
| Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
27 Nov, 2027
(3 years from now)
| Active |
| US8877938 | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
27 May, 2027
(2 years from now)
| Active |
| US9388134
(Pediatric)
| Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
08 May, 2027
(2 years from now)
| Active |
| US9388134 | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
08 Nov, 2026
(2 years from now)
| Active |
| US8101659
(Pediatric)
| Methods of treatment and pharmaceutical composition |
15 Jul, 2025
(9 months from now)
| Active |
| US8101659 | Methods of treatment and pharmaceutical composition |
15 Jan, 2025
(3 months from now)
| Active |
| US7468390
(Pediatric)
| Methods of treatment and pharmaceutical composition |
27 May, 2024
(3 months ago)
| Expired |
| US7468390 | Methods of treatment and pharmaceutical composition |
27 Nov, 2023
(9 months ago)
| Expired |
| US8404744
(Pediatric)
| Methods of treatment and pharmaceutical composition |
14 Jul, 2023
(1 year, 2 months ago)
| Expired |
| US8796331
(Pediatric)
| Methods of treatment and pharmaceutical composition |
14 Jul, 2023
(1 year, 2 months ago)
| Expired |
| US8404744 | Methods of treatment and pharmaceutical composition |
14 Jan, 2023
(1 year, 8 months ago)
| Expired |
| US8796331 | Methods of treatment and pharmaceutical composition |
14 Jan, 2023
(1 year, 8 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Entresto's drug page
2. Jadenu
Jadenu is protected by 3 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9283209 | Oral formulations of deferasirox |
21 Nov, 2034
(10 years from now)
| Active |
| US6465504 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
05 Apr, 2019
(5 years ago)
| Expired |
| US6596750 | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
24 Jun, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jadenu's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List